Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy

Trial Profile

Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Gemcitabine (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 20 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 07 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top